Guardant Health, Inc. (GH)

$26.91

+0.58

(+2.2%)▲

Market is closed - opens 8 PM, 05 Dec 2023

Insights on Guardant Health, Inc.

  • Increasing Revenue

    Revenue is up for the last 7 quarters, 96.09M → 143.03M (in $), with an average increase of 6.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -72.77M → -86.10M (in $), with an average decrease of 18.3% per quarter

  • Vs IDXX

    In the last 1 year, Idexx Laboratories, Inc. has given 10.9% return, outperforming this stock by 62.0%

  • Vs IQV

    In the last 3 years, Iqvia Holdings Inc. has given 5.6% return, outperforming this stock by 84.3%

Performance

  • $26.36
    $27.53
    $26.91
    downward going graph

    2.04%

    Downside

    Day's Volatility :4.25%

    Upside

    2.25%

    downward going graph
  • $20.67
    $54.15
    $26.91
    downward going graph

    23.19%

    Downside

    52 Weeks Volatility :61.83%

    Upside

    50.3%

    downward going graph

Returns

PeriodGuardant Health, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-25.43%
-1.3%
0.0%
6 Months
-18.71%
1.2%
0.0%
1 Year
-49.32%
-5.7%
-6.5%
3 Years
-78.71%
17.1%
-6.5%

Highlights

Market Capitalization
2.8B
Book Value
$1.94
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.03
Wall Street Target Price
49.22
Profit Margin
-80.69%
Operating Margin TTM
-79.03%
Return On Assets TTM
-18.52%
Return On Equity TTM
-218.88%
Revenue TTM
535.8M
Revenue Per Share TTM
4.96
Quarterly Revenue Growth YOY
21.8%
Gross Profit TTM
293.2M
EBITDA
-476.2M
Diluted Eps TTM
-4.03
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.59
EPS Estimate Next Year
-3.32
EPS Estimate Current Quarter
-0.95
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    89%Buy
    10%Hold
    0
    0%Sell
Based on 28 Wall street analysts offering stock ratings for Guardant Health, Inc.(by analysts ranked 0 to 5 stars)
Based on 28 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
25
24
24
Hold
3
3
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 82.91%

Current $26.91
Target $49.22

Company Financials

FY17Y/Y Change
Revenue
49.8M
↑ 97.4%
Net Income
-83.2M
↑ 80.37%
Net Profit Margin
-166.97%
↑ 15.77%
FY18Y/Y Change
Revenue
90.6M
↑ 81.85%
Net Income
-85.1M
↑ 2.21%
Net Profit Margin
-93.85%
↑ 73.12%
FY19Y/Y Change
Revenue
214.4M
↑ 136.52%
Net Income
-67.9M
↓ 20.23%
Net Profit Margin
-31.65%
↑ 62.2%
FY20Y/Y Change
Revenue
286.7M
↑ 33.75%
Net Income
-246.3M
↑ 262.98%
Net Profit Margin
-85.89%
↓ 54.24%
FY21Y/Y Change
Revenue
373.7M
↑ 30.32%
Net Income
-384.8M
↑ 56.23%
Net Profit Margin
-102.98%
↓ 17.09%
FY22Y/Y Change
Revenue
449.5M
↑ 20.31%
Net Income
-654.6M
↑ 70.12%
Net Profit Margin
-145.61%
↓ 42.63%
Q2 FY22Q/Q Change
Revenue
109.1M
↑ 13.57%
Net Income
-229.4M
↑ 86.18%
Net Profit Margin
-210.21%
↓ 81.98%
Q3 FY22Q/Q Change
Revenue
117.4M
↑ 7.57%
Net Income
-162.0M
↓ 29.39%
Net Profit Margin
-137.98%
↑ 72.23%
Q4 FY22Q/Q Change
Revenue
126.9M
↑ 8.08%
Net Income
-139.9M
↓ 13.62%
Net Profit Margin
-110.28%
↑ 27.7%
Q1 FY23Q/Q Change
Revenue
128.7M
↑ 1.44%
Net Income
-133.5M
↓ 4.57%
Net Profit Margin
-103.74%
↑ 6.54%
Q2 FY23Q/Q Change
Revenue
137.2M
↑ 6.55%
Net Income
-72.8M
↓ 45.5%
Net Profit Margin
-53.06%
↑ 50.68%
Q3 FY23Q/Q Change
Revenue
143.0M
↑ 4.29%
Net Income
-86.1M
↑ 18.32%
Net Profit Margin
-60.2%
↓ 7.14%
FY17Y/Y Change
Total Assets
342.9M
↑ 194.2%
Total Liabilities
34.3M
↓ 6.88%
FY18Y/Y Change
Total Assets
587.4M
↑ 71.29%
Total Liabilities
62.5M
↑ 81.9%
FY19Y/Y Change
Total Assets
962.5M
↑ 63.86%
Total Liabilities
114.5M
↑ 83.41%
FY20Y/Y Change
Total Assets
2.3B
↑ 136.02%
Total Liabilities
916.2M
↑ 699.87%
FY21Y/Y Change
Total Assets
2.2B
↓ 2.96%
Total Liabilities
1.6B
↑ 70.22%
FY22Y/Y Change
Total Assets
1.6B
↓ 26.97%
Total Liabilities
1.5B
↓ 0.62%
Q2 FY22Q/Q Change
Total Assets
1.9B
↓ 12.95%
Total Liabilities
1.5B
↓ 3.88%
Q3 FY22Q/Q Change
Total Assets
1.7B
↓ 8.2%
Total Liabilities
1.5B
↑ 0.03%
Q4 FY22Q/Q Change
Total Assets
1.6B
↓ 5.39%
Total Liabilities
1.5B
↑ 0.96%
Q1 FY23Q/Q Change
Total Assets
1.5B
↓ 6.11%
Total Liabilities
1.6B
↑ 0.41%
Q2 FY23Q/Q Change
Total Assets
1.8B
↑ 21.72%
Total Liabilities
1.5B
↓ 0.57%
Q3 FY23Q/Q Change
Total Assets
1.8B
↓ 2.33%
Total Liabilities
1.6B
↑ 1.4%
FY17Y/Y Change
Operating Cash Flow
-72.2M
↑ 96.77%
Investing Cash Flow
-170.4M
↓ 750.39%
Financing Cash Flow
281.7M
↑ 606.97%
FY18Y/Y Change
Operating Cash Flow
-72.2M
↓ 0.07%
Investing Cash Flow
-153.0M
↓ 10.2%
Financing Cash Flow
293.2M
↑ 4.08%
FY19Y/Y Change
Operating Cash Flow
-47.1M
↓ 34.7%
Investing Cash Flow
-317.6M
↑ 107.52%
Financing Cash Flow
367.3M
↑ 25.29%
FY20Y/Y Change
Operating Cash Flow
-103.9M
↑ 120.49%
Investing Cash Flow
-617.1M
↑ 94.31%
Financing Cash Flow
1.4B
↑ 283.96%
FY21Y/Y Change
Operating Cash Flow
-209.0M
↑ 101.12%
Investing Cash Flow
-63.2M
↓ 89.77%
Financing Cash Flow
-66.8M
↓ 104.74%
FY22Y/Y Change
Operating Cash Flow
-309.5M
↑ 48.06%
Investing Cash Flow
149.8M
↓ 337.22%
Financing Cash Flow
-189.1M
↑ 182.97%
Q2 FY22Q/Q Change
Operating Cash Flow
-111.9M
↑ 291.12%
Investing Cash Flow
-72.9M
↓ 165.78%
Financing Cash Flow
-172.1M
↑ 1433958.33%
Q3 FY22Q/Q Change
Operating Cash Flow
-78.2M
↓ 30.17%
Investing Cash Flow
41.3M
↓ 156.62%
Financing Cash Flow
-19.3M
↓ 88.78%
Q4 FY22Q/Q Change
Operating Cash Flow
-90.7M
↑ 16.11%
Investing Cash Flow
70.6M
↑ 71.12%
Financing Cash Flow
2.3M
↓ 112.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-74.4M
↓ 17.97%
Investing Cash Flow
157.2M
↑ 122.61%
Financing Cash Flow
-854.0K
↓ 136.84%
Q2 FY23Q/Q Change
Operating Cash Flow
-94.0M
↑ 26.29%
Investing Cash Flow
-241.1M
↓ 253.37%
Financing Cash Flow
383.9M
↓ 45047.78%

Technicals Summary

Sell

Neutral

Buy

Guardant Health, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Guardant Health, Inc.
Guardant Health, Inc.
-5.08%
-18.71%
-49.32%
-78.71%
-37.99%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
14.08%
3.72%
14.28%
5.57%
145.22%
Agilent Technologies Inc.
Agilent Technologies Inc.
19.77%
8.82%
-15.66%
11.85%
76.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
9.03%
-4.33%
-10.96%
4.53%
103.42%
Danaher Corp.
Danaher Corp.
14.3%
-4.14%
-16.6%
-0.42%
110.24%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
9.33%
6.32%
2.35%
27.14%
76.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Guardant Health, Inc.
Guardant Health, Inc.
NA
NA
NA
-3.59
-2.19
-0.19
0.0
1.94
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.79
48.79
7.21
9.84
0.93
0.24
0.01
15.62
Agilent Technologies Inc.
Agilent Technologies Inc.
33.15
33.15
2.36
5.41
0.22
0.08
0.01
20.01
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
32.16
32.16
4.28
21.56
0.13
0.05
0.0
117.32
Danaher Corp.
Danaher Corp.
27.92
27.92
3.24
7.55
0.12
0.05
0.0
70.93
Iqvia Holdings Inc.
Iqvia Holdings Inc.
35.36
35.36
1.48
10.19
0.2
0.05
0.0
31.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Guardant Health, Inc.
Guardant Health, Inc.
Buy
$2.8B
-37.99%
NA
-80.69%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.7B
145.22%
48.79
22.93%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$37.0B
76.64%
33.15
18.15%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$189.6B
103.42%
32.16
13.68%
Danaher Corp.
Danaher Corp.
Buy
$163.6B
110.24%
27.92
20.01%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$38.5B
76.13%
35.36
7.51%

Institutional Holdings

  • Vanguard Group Inc

    9.16%

  • BlackRock Inc

    8.20%

  • FMR Inc

    7.46%

  • AllianceBernstein L.P.

    3.78%

  • T. Rowe Price Associates, Inc.

    3.57%

  • Eventide Asset Management, LLC

    3.40%

Corporate Announcements

  • Guardant Health, Inc. Earnings

    Guardant Health, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.

Organization
Guardant Health, Inc.
Employees
1793
CEO
Dr. Helmy Eltoukhy Ph.D.
Industry
Health Services

Discover More

FAQs